Contacts NANTES, France, June 24, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported that all 42 resolutions submitted to a vote at the Combined General Shareholders' Meeting held today were approved, with the exception of two of them (resolutions 7 and 14) being rejected as proposed by the Board of Directors. Full results are available on the Company's website (www.ose-immuno.com), "Investors – General Shareholders' Meetings" section. ABOUT OSE IM ...